Safety and efficacy of paclitaxel drug-coated balloon in femoropopliteal in-stent restenosis.
Mahesh Anantha NarayananKeith LoveSameer NagpalAzfar Bilal SheikhChristopher J ReganCarlos Mena-HurtadoPublished in: Expert review of medical devices (2020)
Currently available data supports the use of DCBs as a first-line therapy in patients with FP ISR, with lower rates of TLR and higher patency rates at 1-year follow-up, when compared to POBA. Further randomized studies are essential to evaluate longer term safety and efficacy of DCBs.
Keyphrases
- double blind
- open label
- toll like receptor
- inflammatory response
- electronic health record
- immune response
- preterm infants
- placebo controlled
- big data
- phase iii
- case control
- emergency department
- randomized controlled trial
- gestational age
- stem cells
- drug induced
- bone marrow
- machine learning
- nuclear factor
- study protocol
- replacement therapy